Toni Gómez Centeno

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Sorry, we do not have enough data to show an influence graph for this author.
Learn More
Abatacept and rituximab are two biologic drugs approved in patients with rheumatoid arthritis who have an inadequate response or intolerance to other disease modifying antirheumatic drugs, including one or more tumor necrosis factor (TNF) inhibitors. The current indication for use is the only thing that both drugs have in common because they are different(More)
  • 1